{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T20:34:29Z","timestamp":1794170069387,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The scientific research program of shanghai Pudong New Area Health Commission","award":["PW2022A-18"],"award-info":[{"award-number":["PW2022A-18"]}]},{"name":"the medical discipline construction program of Shanghai Pudong New Area Health Commission Discipline","award":["PWZxk2022-28"],"award-info":[{"award-number":["PWZxk2022-28"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01705-3","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:09:45Z","timestamp":1749269385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Silencing of STX4 inhibits the proliferation, migration and invasion of ovarian cancer cells via EMT\/MMP2\/ CCND1 signaling pathway"],"prefix":"10.1186","volume":"18","author":[{"given":"Wenfeng","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"1705_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL et al. Cancer Statistics. CA Cancer J Clin, 2021;71(1):7\u201333.","DOI":"10.3322\/caac.21654"},{"issue":"1","key":"1705_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1705_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12905-023-02384-2","volume":"23","author":"R Duan","year":"2023","unstructured":"Duan R, et al. Temporal trends and projections of gynecological cancers in China, 2007\u20132030. BMC Womens Health. 2023;23(1):346.","journal-title":"BMC Womens Health"},{"issue":"4","key":"1705_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1705_CR5","first-page":"4766","volume":"61","author":"EY Woo","year":"2001","unstructured":"Woo EY, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61(12):4766\u201372.","journal-title":"Cancer Res"},{"issue":"1","key":"1705_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R De Angelis","year":"2014","unstructured":"De Angelis R, et al. Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE\u20135-a population-based study. Lancet Oncol. 2014;15(1):23\u201334.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1705_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ejca.2007.12.015","volume":"44","author":"HE Karim-Kos","year":"2008","unstructured":"Karim-Kos HE, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345\u201389.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1705_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3892\/ijo.2014.2311","volume":"44","author":"KD Steffensen","year":"2014","unstructured":"Steffensen KD, et al. Resistance to first line platinum Paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. Int J Oncol. 2014;44(5):1736\u201344.","journal-title":"Int J Oncol"},{"issue":"182","key":"1705_CR9","first-page":"1471","volume":"6","author":"G Ferrandina","year":"2006","unstructured":"Ferrandina G, et al. Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum\/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer. 2006;6(182):1471\u20132407.","journal-title":"BMC Cancer"},{"issue":"9","key":"1705_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1136\/ijgc-2019-000624","volume":"29","author":"A Bergamini","year":"2019","unstructured":"Bergamini A, et al. Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option. Int J Gynecol Cancer. 2019;29(9):1431\u20136.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1705_CR11","doi-asserted-by":"publisher","first-page":"021","DOI":"10.1186\/s10020-021-00295-2","volume":"27","author":"A Sipos","year":"2021","unstructured":"Sipos A, et al. The role of the Microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Mol Med. 2021;27(1):021\u201300295.","journal-title":"Mol Med"},{"key":"1705_CR12","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1002\/cncr.32496","volume":"24","author":"I Vergote","year":"2019","unstructured":"Vergote I, Harter P, Chiva L. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. Cancer. 2019;24:4594\u20137.","journal-title":"Cancer"},{"issue":"55","key":"1705_CR13","first-page":"619","volume":"17","author":"DM O\u2019Malley","year":"2019","unstructured":"O\u2019Malley DM. New therapies for ovarian Cancer. J Natl Compr Canc Netw. 2019;17(55):619\u201321.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"1705_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","volume":"33","author":"JS Frenel","year":"2022","unstructured":"Frenel JS, et al. Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on Olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial. Ann Oncol. 2022;33(10):1021\u20138.","journal-title":"Ann Oncol"},{"issue":"25","key":"1705_CR15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, et al. Olaparib plus bevacizumab as First-Line maintenance in ovarian Cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"25","key":"1705_CR16","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, et al. Niraparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"1","key":"1705_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/21645515.2023.2198467","volume":"19","author":"RO Dillman","year":"2023","unstructured":"Dillman RO, Nistor GI, Keirstead HS. Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines. Hum Vaccin Immunother. 2023;19(1):3.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"1705_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1705_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1541-7786.MCR-20-0527","volume":"20","author":"MI Brasher","year":"2022","unstructured":"Brasher MI, et al. Syntaxin4-Munc18c interaction promotes breast tumor invasion and metastasis by regulating MT1-MMP trafficking. Mol Cancer Res. 2022;20(3):434\u201345.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1705_CR20","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1186\/s12885-021-08736-1","volume":"21","author":"L He","year":"2021","unstructured":"He L, et al. Up-regulation expression and prognostic significance of Syntaxin4 in kidney renal clear cell carcinoma. BMC Cancer. 2021;21(1):992.","journal-title":"BMC Cancer"},{"issue":"4","key":"1705_CR21","first-page":"863","volume":"39","author":"P Day","year":"2011","unstructured":"Day P, et al. Syntaxins 3 and 4 mediate vesicular trafficking of \u03915\u03b21 and \u03913\u03b21 integrins and cancer cell migration. Int J Oncol. 2011;39(4):863\u201371.","journal-title":"Int J Oncol"},{"issue":"10","key":"1705_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","volume":"30","author":"B Bakir","year":"2020","unstructured":"Bakir B, et al. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 2020;30(10):764\u201376.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"1705_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13048-023-01304-0","volume":"16","author":"GA Ferreira","year":"2023","unstructured":"Ferreira GA, et al. Proteomic analysis of exosomes secreted during the epithelial-mesenchymal transition and potential biomarkers of mesenchymal high-grade serous ovarian carcinoma. J Ovarian Res. 2023;16(1):232.","journal-title":"J Ovarian Res"},{"issue":"2","key":"1705_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21037\/tcr.2019.02.11","volume":"8","author":"W Ye","year":"2019","unstructured":"Ye W, et al. STX4 expression is associated with classification, clinical stage and lymphatic metastasis in ovarian cancer. Transl Cancer Res. 2019;8(2):466\u201372.","journal-title":"Transl Cancer Res"},{"key":"1705_CR25","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin, 2015;65(1):5\u201329.","DOI":"10.3322\/caac.21254"},{"issue":"1","key":"1705_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1705_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ygyno.2008.01.033","volume":"109","author":"M Choi","year":"2008","unstructured":"Choi M, et al. Conditional survival in ovarian cancer: results from the SEER dataset 1988\u20132001. Gynecol Oncol. 2008;109(2):203\u20139.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"1705_CR28","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/1541-7786.MCR-12-0353","volume":"10","author":"N Musrap","year":"2012","unstructured":"Musrap N, Diamandis EP. Revisiting the complexity of the ovarian cancer microenvironment\u2013clinical implications for treatment strategies. Mol Cancer Res. 2012;10(10):1254\u201364.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1705_CR29","doi-asserted-by":"publisher","first-page":"e23918","DOI":"10.1016\/j.heliyon.2023.e23918","volume":"10","author":"K Zeng","year":"2024","unstructured":"Zeng K, et al. STX4 as a potential biomarker for predicting prognosis and guiding clinical treatment decisions in clear cell renal cell carcinoma. Heliyon. 2024;10(1):e23918.","journal-title":"Heliyon"},{"issue":"18","key":"1705_CR30","doi-asserted-by":"publisher","first-page":"e108647","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, et al. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40(18):e108647.","journal-title":"EMBO J"},{"issue":"17","key":"1705_CR31","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","volume":"27","author":"M Taki","year":"2021","unstructured":"Taki M, et al. Tumor immune microenvironment during Epithelial-Mesenchymal transition. Clin Cancer Res. 2021;27(17):4669\u201379.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1705_CR32","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/1759-7714.13906","volume":"12","author":"Q Qin","year":"2021","unstructured":"Qin Q, et al. Targeting the EMT transcription factor snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer. Thorac Cancer. 2021;12(11):1708\u201315.","journal-title":"Thorac Cancer"},{"key":"1705_CR33","doi-asserted-by":"crossref","unstructured":"Cortes-Dericks L, Galetta D. Impact of Cancer stem cells and Cancer stem Cell-Driven drug resiliency in lung tumor: options in sight. Cancers (Basel), 2022;14(2).","DOI":"10.3390\/cancers14020267"},{"key":"1705_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-0716-3589-6_16","volume":"2747","author":"AM Knapinska","year":"2024","unstructured":"Knapinska AM, et al. Analysis of matrix metalloproteinase activity and Inhibition in Cancer spheroids. Methods Mol Biol. 2024;2747:189\u2013209.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1705_CR35","first-page":"52","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators Tumor Microenvironment Cell. 2010;141(1):52\u201367.","journal-title":"Matrix Metalloproteinases: Regulators Tumor Microenvironment Cell"},{"issue":"19\u201320","key":"1705_CR36","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.cca.2011.06.003","volume":"412","author":"M Lukaszewicz-Zajac","year":"2011","unstructured":"Lukaszewicz-Zajac M, Mroczko B, Szmitkowski M. Gastric cancer - The role of matrix metalloproteinases in tumor progression. Clin Chim Acta. 2011;412(19\u201320):1725\u201330.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1705_CR37","doi-asserted-by":"publisher","first-page":"9290","DOI":"10.1080\/21655979.2021.2000225","volume":"12","author":"LL Quan","year":"2021","unstructured":"Quan LL, et al. Expression of Cyclin D1 gene in ovarian cancer and effect of Silencing its expression on ovarian cancer cells based on the Oncomine database. Bioengineered. 2021;12(2):9290\u2013300.","journal-title":"Bioengineered"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01705-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:09:48Z","timestamp":1749269388000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01705-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01705-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}